U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C38H47ClN4O4
Molecular Weight 659.257
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CGM-097

SMILES

COC1=CC2=C(C=C1OC(C)C)[C@@H](N(C(=O)C2)C3=CC=C(C=C3)N(C)C[C@H]4CC[C@@H](CC4)N5CCN(C)C(=O)C5)C6=CC=C(Cl)C=C6

InChI

InChIKey=CLRSLRWKONPSRQ-IIPSPAQQSA-N
InChI=1S/C38H47ClN4O4/c1-25(2)47-35-22-33-28(20-34(35)46-5)21-36(44)43(38(33)27-8-10-29(39)11-9-27)32-16-14-30(15-17-32)41(4)23-26-6-12-31(13-7-26)42-19-18-40(3)37(45)24-42/h8-11,14-17,20,22,25-26,31,38H,6-7,12-13,18-19,21,23-24H2,1-5H3/t26-,31-,38-/m0/s1

HIDE SMILES / InChI

Approval Year

Name Type Language
CGM-097
Code English
CGM 097
Code English
NVP-CGM-097
Code English
3(2H)-ISOQUINOLINONE, 1-(4-CHLOROPHENYL)-1,4-DIHYDRO-6-METHOXY-7-(1-METHYLETHOXY)-2-(4-(METHYL((TRANS-4-(4-METHYL-3-OXO-1-PIPERAZINYL)CYCLOHEXYL)METHYL)AMINO)PHENYL)-, (1S)-
Systematic Name English
(1S)-1-(4-CHLOROPHENYL)-1,4-DIHYDRO-6-METHOXY-7-(1-METHYLETHOXY)-2-(4-(METHYL((TRANS-4-(4-METHYL-3-OXO-1-PIPERAZINYL)CYCLOHEXYL)METHYL)AMINO)PHENYL)-3(2H)-ISOQUINOLINONE
Systematic Name English
CGM 097 [WHO-DD]
Common Name English
CGM097
Code English
Code System Code Type Description
SMS_ID
300000041483
Created by admin on Sat Dec 16 12:07:18 UTC 2023 , Edited by admin on Sat Dec 16 12:07:18 UTC 2023
PRIMARY
CAS
1313363-54-0
Created by admin on Sat Dec 16 12:07:18 UTC 2023 , Edited by admin on Sat Dec 16 12:07:18 UTC 2023
PRIMARY
MANUFACTURER PRODUCT INFORMATION
CGM-097
Created by admin on Sat Dec 16 12:07:18 UTC 2023 , Edited by admin on Sat Dec 16 12:07:18 UTC 2023
PRIMARY Biological Activity: CGM-097 is a potent and selective MDM2 inhibitor.An orally bioavailable HDM2 (human homolog of double minute 2) antagonist with potential antineoplastic activity. Upon oral administration, p53/HDM2 interaction inhibitor CGM097 inhibits the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteosome-mediated enzymatic degradation of p53 is inhibited, which may result in the restoration of p53 signaling and, thus, the p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger nuclear phosphoprotein, is a negative regulator of the p53 pathway, often overexpressed in cancer cells and has been implicated in cancer cell proliferation and survival.
FDA UNII
4UF6MSL0ZH
Created by admin on Sat Dec 16 12:07:18 UTC 2023 , Edited by admin on Sat Dec 16 12:07:18 UTC 2023
PRIMARY
NCI_THESAURUS
C104280
Created by admin on Sat Dec 16 12:07:18 UTC 2023 , Edited by admin on Sat Dec 16 12:07:18 UTC 2023
PRIMARY